Revolution Medicines, Inc.
NASDAQ:RVMDBiotechnology
+$3.60 today
- Market cap
- $34.57B
- Beta
- 1.41
- P/E (TTM)
- -23.3
- EPS (TTM)
- -$6.92
Volume 2.34M
Average 3.10M
RVMD Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Revolution Medicines, Inc.NASDAQ: RVMD
Cash & Equivalents · Q2 FY2026 · quarter ended Jun 2026
Cash & equivalents rises 102.6% from a year ago
Cash & equivalents stood at $815.44M at the end of Q2 FY2026, up 102.6% from a year earlier and up 84.9% from the prior quarter. Over 3 fiscal years it compounded at +33.5% a year.
Context
- Cash & equivalents amounted to 18.9% of total assets at the end of Q2 FY2026, up 2.3 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +102.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 383.75M USD
- Year-over-year change
- -29.3%
- 4-year CAGR
- +37.1%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 383.75M | -29.3% |
| FY2024 | 2024-12-31 | 543.06M | -22.0% |
| FY2023 | 2023-12-31 | 696.15M | +331.3% |
| FY2022 | 2022-12-31 | 161.41M | +48.8% |
| FY2021 | 2021-12-31 | 108.5M | — |
Cash & Equivalents vs competitors
How RVMD compares with its peers on the latest reported figures
- RVMD's Jun 2026 cash & equivalents of $815.44M is the highest of the 11 companies compared; the peer median is $136.43M.
- Its year-over-year change of +102.6% is the 3rd highest of 11, against a peer median of +44.8%.
- Cash & equivalents amounts to 18.9% of total assets for RVMD, versus a peer median of 16.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $815.44M | +102.6% | +33.5% | 18.9% | |
| Aug 2026 | $720.24M | +818.2% | +56.5% | 60.3% | |
| Mar 2026 | $165.55M | +40.8% | +39.9% | 72.7% | |
| Mar 2026 | $159.86M | +103.6% | +33.2% | 21.7% | |
| Mar 2026 | $157.52M | +21.2% | +18.0% | 15.3% | |
| Sep 2026 | $151.67M | +49.1% | +9.4% | 16.9% | |
| Jun 2026 | $121.19M | +6.4% | -17.9% | 12.5% | |
| Sep 2026 | $118.96M | +69.4% | -36.2% | 11.9% | |
| Sep 2026 | $86.84M | +48.8% | +23.3% | 8.4% | |
| Mar 2026 | $56.4M | +14.3% | -11.9% | 12.9% | |
| Mar 2026 | $30.07M | -69.4% | -15.1% | 22.6% | |
| Peer median (excluding RVMD) | $136.43M | +44.8% | +13.7% | 16.1% | |
Competitors are the stored peer set for RVMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 108.5M | 161.41M | 696.15M | 543.06M | 383.75M |
| Short-term Investments | 468.56M | 483.53M | 1.16B | 1.75B | 1.64B |
| Net Receivables | 5.93M | 4.67M | 1.25M | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 10.57M | 25.07M | 38.33M | 49.36M |
| Total Current Assets | 589.77M | 660.19M | 1.88B | 2.33B | 2.08B |
| Property, Plant & Equipment (Net) | 71.24M | 73.74M | 100.01M | 141.82M | 165.28M |
| Goodwill | 14.61M | 14.61M | 14.61M | 14.61M | 14.61M |
| Intangible Assets | 59.88M | 58.81M | 57.74M | 56.67M | 55.8M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 2.5M | 4.59M | 10.06M | 17.57M | 43.79M |
| Total Non-current Assets | 148.22M | 151.75M | 182.42M | 230.67M | 279.47M |
| Total Assets | 737.99M | 811.93M | 2.06B | 2.56B | 2.35B |
| Account Payables | 14.06M | 21.31M | 61.79M | 54.43M | 64.62M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 12.36M | 4.46M | 0 | 0 | 0 |
| Other Current Liabilities | 10.16M | 13.79M | 27.51M | 31.36M | 66.05M |
| Total Current Liabilities | 60.35M | 61.98M | 143.85M | 163.91M | 290.42M |
| Long-term Debt | 0 | 0 | 0 | 0 | 142.23M |
| Deferred Tax Liabilities | 7.44M | 7.03M | 3.12M | 2.35M | 2.35M |
| Deferred Revenue (Non-current) | 6.57M | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 634K | 301K | 7.97M | 3.86M | 288.2M |
| Total Non-current Liabilities | 75.07M | 64.76M | 91.66M | 129.18M | 432.79M |
| Total Liabilities | 135.42M | 126.74M | 235.51M | 293.1M | 723.21M |
| Common Stock | 8K | 9K | 16K | 18K | 19K |
| Retained Earnings | (452.64M) | (701.34M) | (1.14B) | (1.74B) | (2.87B) |
| Accumulated OCI | (376K) | (1.78M) | 544K | 1.32M | 3.24M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 602.57M | 685.19M | 1.83B | 2.27B | 1.63B |
| Total Debt | 66.63M | 64.21M | 87.94M | 135.84M | 158.7M |
| Net Debt | (41.86M) | (97.21M) | (608.2M) | (407.22M) | (225.04M) |
Revolution Medicines, Inc.
NASDAQ:RVMD
Intrinsic Alpha fair value
Locked
Current Price
$159.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.